Ranbaxy Wins U.S. Approval to Sell Generic of Pfizer’s Lipitor
The Food and Drug Administration approved Ranbaxy’s copy of the world’s top-selling drug, which will be manufactured by Ohm Laboratories in New Brunswick, New Jersey, the agency said today in a statement. Watson Pharmaceuticals Inc. (WPI) today began selling a copy of Lipitor in the U.S. under an agreement with New York- based Pfizer. Watson’s version didn’t require FDA clearance because Pfizer is providing the drug to sell without the brand label in return for a share of the revenue.
To contact the reporter on this story: Molly Peterson in Washington at email@example.com
To contact the editor responsible for this story: Adriel Bettelheim at firstname.lastname@example.org